You are here

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Last updated on March 20, 2019

FOR MORE INFORMATION
Study Location
Nagoya Daini Red Cross Hospital
Aichi, , 466-8650 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
B-Cell Lymphoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.

- Prior therapy must have contained at least one dose of Rituximab therapy. Patients can
not be refractory to Rituximab (refractory = PD under treatment or within 6 month

- Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.

- Patients must not have received previous radioimmunotherapy.

- Patients tolerant to Rituximab.

- Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth
factors (except erythropoietin), or investigational agents within 28 days before first
dose of test article.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Candidate for potentially curative therapies

- Subjects must not have received previous radioimmunotherapy.

- Subjects with autologous hematopoietic stem cell transplant within the last 6 months

NCT00724971
Pfizer
Completed
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03460977
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now